Drug combinations make sense both from the science and from the business perspective.
Like systematic drug repurposing, big data analytics recognises that there is value in “knowing what we know”. Both can lead to innovation and both can play a significant role in shaping the healthcare environment of the future.
Recent Biovista work that shows it is possible to predict risk factors reliably, clears the way to systematic use of this capability by the healthcare industry.
Andreas Persidis, CEO In a recent post at the Drug Repositioning discussion group of LinkedIn, John Waslif alerted the community to an interesting article by Michael Kinch titled “The Process by which Drugs are Discovered and Developed will be Fundamentally Different in the Future”. I guess no one will argue with such a statement. What … Read More
Knowledge recycling – i.e. reusing, recombining and contextualizing – must be recognised as a powerful approach to systematic innovation, especially for the biopharmaceutical industry. We should openly discuss its value and start using processes, tools and business models that make it an integral part of our business activities.